For this level of weight loss, expect appetite suppression to build gradually over the first 8-12 weeks, then sustain at a high level throughout the treatment period
Noteworthy is the fact that, in our study, no significant correlations were observed between %WR and fasting GIP and GLP-1 levels, while it is the response to the mixed meal that is distinct, which suggests that the BMI is unlikely to be the sole reason for the differences observed
Vomiting after meals, persistent abdominal discomfort, or difficulty eating normal portions may appear
Subcutaneous administration is required (daily in two doses for exenatide, one for liraglutide and lixisenatide, and weekly for exenatide-LAR [long-acting release] and dulaglutide), as well as training regarding the potential adverse effects